Pethidine is named as an intervention in 3 current clinical trials in our Italy, Singapore and Israel registers. 1 is recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Fondazione Andrea Cesalpino Arezzo ONLUS (1). The most-studied condition is Sedation During Bronchoscopy.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Combined Intravenous Tramadol and Paracetamol Versus Intramuscular Pethidine for Pain Relief During the First Stage of Labor. Compare the Efficacy and Adverse Effects
NCT07264309 · ClinicalTrials.gov ↗ · Pain Management, Birth
|
Not applicable | Recruiting | Zohar Nachum | Israel |
|
Balanced Analgosedation in Bronchoscopy: Propofol/Pethidine Versus Midazolam/Pethidine
NCT06736938 · ClinicalTrials.gov ↗ · Sedation During Bronchoscopy
|
Phase 4 | Not yet open | Fondazione Andrea Cesalpino Arezzo ONLUS | Italy |
|
CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery)
NCT03167905 · ClinicalTrials.gov ↗ · Depression, Postpartum, Analgesia, Obstetrical, Anesthesia, Obstetrical
|
Phase 2/3 | Active, closed | KK Women's and Children's Hospital | Singapore |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Pethidine on the HPRA medicines list.
No entry for Pethidine in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Fondazione Andrea Cesalpino Arezzo ONLUS | 1 |
| KK Women's and Children's Hospital | 1 |
| Zohar Nachum | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Italy | 1 | 0 |
| Clinical trials in Singapore | 1 | 0 |
| Clinical trials in Israel | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Italy, Singapore and Israel registers name Pethidine as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Fondazione Andrea Cesalpino Arezzo ONLUS (1), KK Women's and Children's Hospital (1) and Zohar Nachum (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Pethidine, for example Pethidine Hydrochloride 50mg/ml Solution for Injection (Mercury Pharmaceuticals (Ireland) Ltd). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Pethidine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pethidine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pethidine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pethidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.